HUM vs MDGL: fair value comparison
Humana Inc. and Madrigal Pharmaceuticals, Inc. · Updated 2026-10-19
MDGL's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, HUM currently ranks higher by quality score.
| HUM | MDGL | |
|---|---|---|
| Verdict | Overvalued | Awaiting full valuation |
| Last price | $431.87 | $449.74 |
| 12-month range | $163.67–$433.50 | $412.35–$602.83 |
| Rank by discount to fair value | #90 of 108 Healthcare | — |
| Rank by quality score | #199 of 301 Healthcare | #200 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | Moderate |
| Margin trend | Contracting | Contracting |
| Revenue growth | Strong | — |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | — | Mixed |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: HUM fair value analysis · MDGL fair value analysis